Influence of different drug delivery methods for Endostar combined with a gemcitabine/cisplatin regimen in locally advanced or metastatic lung squamous cell carcinoma

Abstract

Continuous endovenous administration of Endostar (CE) gradually replaced drip intravenous administration of Endostar (DE) in lung squamous cell carcinoma (SCC) treatment presently, but the efficacy and safety of CE and DE which is better in advanced lung SCC are yet unclear. To evaluate the feasibility of CE as an alternative to DE with gemcitabine/cisplatin (GP) chemotherapy. Data were collected from patients admitted with locally advanced or metastatic lung SCC from January 2011 to April 2015, including the patients’ characteristics, the therapeutic regimen, the treatment effectiveness, and toxicity. There are 71 patients with pathologically confirmed lung SCC retrospectively assigned to a treatment (CE) group of 48 patients and a control (DE) group of 23 patients. The response of each tumor to the therapy was assessed every 2 cycles by a chest and upper abdomen computed tomography for the comparison of curative effects and adverse reactions. Compared with the DE group, the response rate and disease control rate were noninferior in the CE group. The median progression-free survival and overall survival in the CE and DE groups were no significantly difference (5.5 vs 5.5 months, P = .141; 22.9 vs 14.3 months, P = .053). Increased progression-free survival (PFS) for patients in CE group was observed across 3 subgroups analyzed. There was a 35.7% reduction in the total dose of Endostar per cycle in the CE group compared with that in the DE group. Thus, in combination with GP chemotherapy, CE could be a suitable alternative to DE in locally advanced or metastatic SCC patients, resulting in less hemoptysis, less treatment time, and lower costs.

Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non‐small cell lung cancer: Updated follow‐up results from two phase II trials

“…In the report by Li et al 18 advanced NSCLC treated with CIV Endostar combined with chemotherapy showed a significantly higher disease control rate (86.2% vs. 70.7%, P < 0.01), longer median PFS (six months vs. four months, P = 0.037) and median OS (17.5 months vs. 13.5 months, P = 0.034) compared with IV Endostar combined with chemotherapy. The trend seen in the single-center retrospective study by Cheng et al19 was similar to that in the report by Li et al Yao et al 20 retrospectively compared the efficacy of CIV Endostar to IV Endostar in advanced or metastatic lung squamous cell carcinoma, both combined with gemcitabine/cisplatin chemotherapy (GP regimen). The median OS in the CIV group appeared to be longer compared with the IV group (22.9 months vs. 14.3 months).…”

“…The trend seen in the single‐center retrospective study by Cheng et al .19 was similar to that in the report by Li et al . Yao et al . retrospectively compared the efficacy of CIV Endostar to IV Endostar in advanced or metastatic lung squamous cell carcinoma, both combined with gemcitabine/cisplatin chemotherapy (GP regimen).…”

Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies

“…Three thousand eight hundred thirty-one records were further excluded as they did not meet the inclusion criteria. Finally, nine studies were identified as eligible for inclusion in this systematic review, including four cohort studies [18][19][20][21] and two RCTs [22,23] and three NRCTs [24][25][26]. Table 1 showed the characteristics of included studies.…”

“…A total of 597 advanced NSCLC participants were included (CIV: 300 and IIV: 297), with ages ranging from 24 to 78 years. The histological types of NSCLC included both SqCC and ADC in five studies [20][21][22][23][24], only SqCC in one study [18], and were unknown in three studies [19,25,26]. TNM staging of advanced NSCLC included both stage III and IV in six studies [18][19][20][22][23][24], only stage IV in one study [26], and were not reported in two studies [21,25].…”

“…In all included studies, Endostar was administered in combination with first-line chemotherapy, and no surgery or radiotherapy was implemented. ORR, DCR and adverse events were reported in all nine studies, OS in two studies [18,19], and PFS in four studies [18][19][20][21].…”